Overview

Neurosoft Bioelectronics is a Swiss neurotech company developing soft, stretchable cortical electrode arrays designed to sit on the surface of the brain without penetrating tissue. The company is an EPFL spinout from Prof. Stéphanie Lacour’s Laboratory for Soft Bioelectronic Interfaces, founded in 2020 and now headquartered at Campus Biotech Geneva.

Founders

Neurosoft was co-founded by Nicolas Vachicouras (CEO), Ludovic Serex, Florian Fallegger, and Prof. Stéphanie Lacour. Vachicouras started in Lacour’s lab as an EPFL microengineering undergraduate intern and progressed through the lab during his PhD before co-founding the company. Serex joined in 2018 with cleanroom microfabrication expertise.

Technology

Neurosoft’s electrode platform is described as 1,000 to 100,000 times softer than the materials used in other flexible neural interfaces, and capable of covering up to 30 times more cortex than current state-of-the-art BCIs. The current commercial product is a 64-channel soft, stretchable brain interface designed for intraoperative epilepsy surgery guidance, with the same architecture positioned for downstream chronic implantation in BCI indications. The platform is designed for minimally invasive surgical deployment, lowering the clinical-risk profile compared with intracortical penetrating arrays.

Clinical programme

Neurosoft has tested its 64-channel device in 10 patients across two ongoing clinical trials at UTHealth Houston (United States) and UMC Utrecht (Netherlands), focused on epilepsy surgery guidance. The intraoperative use case is mapping cortical activity during epilepsy resection surgery to help surgeons identify the regions to remove and the regions to spare. The second target indication is severe tinnitus.

May 2026 funding

Neurosoft closed a $7.5 million oversubscribed seed round on 20 May 2026, led by Skybound Venture Capital (Athens-based deeptech fund anchored by the European Investment Fund) with participation from PL Capital, IAG Capital Partners, and Connecticut Innovations. The round brought total funding past $20 million. Neurosoft is Skybound’s inaugural portfolio investment.

Strategic position

Neurosoft is the third Wyss Center / EPFL / Campus Biotech Geneva-adjacent BCI company to advance clinically in 2026, alongside ABILITY Neurotech (Wyss Center spinout) and ONWARD Medical (Courtine / Bloch spinout, NASDAQ + Euronext listed). The company’s soft, surface-electrode architecture differentiates it from penetrating intracortical BCIs while remaining higher-resolution and more cortex-covering than purely non-invasive EEG-based approaches.